Cargando…

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply

Detalles Bibliográficos
Autores principales:	Aomar-Millán, Ismael Francisco, Salvatierra, Juan, Hernández-Quero, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Ce - Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945597/ https://www.ncbi.nlm.nih.gov/pubmed/33694056 http://dx.doi.org/10.1007/s11739-021-02690-3

Ejemplares similares

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience: reply
por: De Monte, Amato, et al.
Publicado: (2021)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
por: Potere, Nicola, et al.
Publicado: (2020)

Delirium in COVID‑19 pneumonia: looking inside the geriatric unit—reply
por: Callea, Antonio, et al.
Publicado: (2022)

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Patient Perspective, Complexities, and Challenges in Managed Care
por: Jan, Saira
Publicado: (2010)

Atrial Fibrillation and Managed Care: Current Approaches and Future Directions for Long-Term Therapy
por: Sanoski, Cynthia A., et al.
Publicado: (2009)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

The need for a correct oxygen-ozone autohemotherapy (O(3)-AHT) in patients with mild to moderate COVID-19 pneumonia
por: Chirumbolo, Salvatore, et al.
Publicado: (2021)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Corticosteroid therapy in patients with heart failure hospitalized for COVID-19: a multicenter retrospective study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

A double-edged sword: e-cigarettes, and other electronic nicotine delivery systems (ENDS): reply
por: Polosa, Riccardo, et al.
Publicado: (2019)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply
por: Farsalinos, Konstantinos, et al.
Publicado: (2020)

Bronchoalveolar lavage findings in severe COVID-19 pneumonia
por: Voiriot, Guillaume, et al.
Publicado: (2020)

Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions-reply
por: Crescioli, Giada, et al.
Publicado: (2021)

Delirium in COVID‑19 pneumonia: looking inside the geriatric unit
por: Vargas, Nicolas, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply
por: Ferrara, Pietro, et al.
Publicado: (2022)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

“To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care”—Reply
por: Lapi, Francesco, et al.
Publicado: (2023)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series
por: Beltrão, Beatriz Amorim, et al.
Publicado: (2021)

Early effects of Anakinra in corticosteroid naïve SOJIA patients
por: Wulffraat, NM, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ma0psr0mls77k9n6kb79ippp7d